Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Lorenz Balcar
  • Mattias Mandorfer
  • Virginia Hernández-Gea
  • Bogdan Procopet
  • Elias Laurin Meyer
  • Álvaro Giráldez
  • Lucio Amitrano
  • Candid Villanueva
  • Dominique Thabut
  • Luis Ibáñez Samaniego
  • Gilberto Silva-Junior
  • Javier Martinez
  • Joan Genescà
  • Christophe Bureau
  • Jonel Trebicka
  • Elba Llop Herrera
  • Wim Laleman
  • José María Palazón Azorín
  • Jose Castellote Alonso
  • Gluud, Lise Lotte
  • Carlos Noronha Ferreira
  • Nuria Cañete
  • Manuel Rodríguez
  • Arnulf Ferlitsch
  • Jose Luis Mundi
  • Henning Grønbæk
  • Manuel Nicolas Hernandez Guerra
  • Romano Sassatelli
  • Alessandra Dell'Era
  • Marco Senzolo
  • Juan Gonzalez Abraldes
  • Manuel Romero-Gómez
  • Alexander Zipprich
  • Meritxell Casas
  • Helena Masnou
  • Massimo Primignani
  • Aleksander Krag
  • Frederik Nevens
  • Jose Luis Calleja
  • Christian Jansen
  • María Vega Catalina
  • Agustín Albillos
  • Marika Rudler
  • Edilmar Alvarado Tapias
  • Maria Anna Guardascione
  • Marcel Tantau
  • Rémy Schwarzer
  • Thomas Reiberger
  • Stig Borbjerg Laursen
  • Marta Lopez-Gomez
  • International Variceal Bleeding Observational Study Group by the Baveno Cooperation: an EASL consortium
Background & Aims
Pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) is the treatment of choice for high-risk acute variceal bleeding (AVB; i.e., Child-Turcotte-Pugh [CTP] B8-9+active bleeding/C10-13). Nevertheless, some ‘non-high-risk’ patients have poor outcomes despite the combination of non-selective beta-blockers and endoscopic variceal ligation for secondary prophylaxis. We investigated prognostic factors for re-bleeding and mortality in ‘non-high-risk’ AVB to identify subgroups who may benefit from more potent treatments (i.e., TIPS) to prevent further decompensation and mortality.

Methods
A total of 2,225 adults with cirrhosis and variceal bleeding were prospectively recruited at 34 centres between 2011-2015; for the purpose of this study, case definitions and information on prognostic indicators at index AVB and on day 5 were further refined in low-risk patients, of whom 581 (without failure to control bleeding or contraindications to TIPS) who were managed by non-selective beta-blockers/endoscopic variceal ligation, were finally included. Patients were followed for 1 year.

Results
Overall, 90 patients (15%) re-bled and 70 (12%) patients died during follow-up. Using clinical routine data, no meaningful predictors of re-bleeding were identified. However, re-bleeding (included as a time-dependent co-variable) increased mortality, even after accounting for differences in patient characteristics (adjusted cause-specific hazard ratio: 2.57; 95% CI 1.43-4.62; p = 0.002). A nomogram including CTP, creatinine, and sodium measured at baseline accurately (concordance: 0.752) stratified the risk of death.

Conclusion
The majority of ‘non-high-risk’ patients with AVB have an excellent prognosis, if treated according to current recommendations. However, about one-fifth of patients, i.e. those with CTP ≥8 and/or high creatinine levels or hyponatremia, have a considerable risk of death within 1 year of the index bleed. Future clinical trials should investigate whether elective TIPS placement reduces mortality in these patients.
OriginalsprogEngelsk
TidsskriftJournal of Hepatology
Vol/bind80
Udgave nummer1
Sider (fra-til)73-81
Antal sider9
ISSN0168-8278
DOI
StatusUdgivet - 2024

Bibliografisk note

Publisher Copyright:
© 2023 European Association for the Study of the Liver

ID: 382441010